– Treatment with Nypta(R) (Tideglusib) (NP-12) was
tolerated and produced positive effects on Alzheimer’s patients in
four of the five efficacy variables examined in the
trial.
– In view of the promising results of this trial, Noscira
is preparing the next Phase IIb trial on Alzheimer’s patients in
order to progress with the clinical development of this novel
compound.
MADRID, July 15 /PRNewswire/ — Noscira, the Grupo
Zeltia (ZEL.MC) subsidiary specialized in researching and
developing drugs for treating neurodegenerative diseases, presented
the results of a Phase IIa clinical trial of Nypta(R) (Tideglusib)
on Alzheimer’s disease (AD) at the International Conference on
Alzheimer’s Disease (ICAD), held in Honolulu (Hawaii) from July
10-15, 2010.
Dr. Teodoro del Ser, Director of
Clinical Development at Noscira, gave an oral session in the
“Therapeutic Strategies” symposium in which he reported that
treatment with Nypta(R) (Tideglusib) for 20 weeks was tolerated and
had a positive impact on patients’ cognitive performance. In order
for these results to be statistically significant, they must be
confirmed in a Phase IIb trial in which a larger group of patients
will be treated for one year.
The Phase IIa trial, which was conducted at three centers in
Germany based on advice from
experts at the European Medicines Agency (EMA), is the first
clinical trial of Nypta(R) (Tideglusib) on a group of Alzheimer’s
patients. The trial was designed with the primary goal of assessing
the safety and tolerability of Nypta(R) (Tideglusib) on these
patients.
The
‘/>”/>
